Chief Financial Officer · Tarsus Pharmaceuticals, Inc. (TARS)

Leo Greenstein

FY2020 is the first fiscal year CompBrief holds for Leo Greenstein as a named executive officer of Tarsus Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$835,443

Salary $256,023Stock awards $0Bonus $147,437

3rd of 3 named executive officers at Tarsus Pharmaceuticals by FY2020 total.

3 named officers on file for Tarsus Pharmaceuticals, FY2020

Leo Greenstein’s pay file — $29

  • 1 fiscal year of pay, line by line
  • TARS’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tarsus Pharmaceuticals’s whole pay program stands against its peers

  • Tarsus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TARS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2021 (DEF 14A).

Free

Get Leo Greenstein’s full pay file as a PDF — free

More than this page: up to 10 years of Leo’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Leo Greenstein compensation by year

Tarsus Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Tarsus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$256,023
Bonus$147,437
Stock awards$0
Option awards$418,703
Non-equity incentive$0
Pension and deferred compensation$0
All other$13,280
Total$835,443

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tarsus Pharmaceuticals, Inc. DEF 14A filed April 30, 2021, accession 0001193125-21-144962, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Tarsus Pharmaceuticals, Inc. filed document, accession 0001193125-21-144962. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU67,316$2,782,170—
Option72,846—$2.01
Option24,252—$10.99

Per the Outstanding Equity Awards at Fiscal Year-End table in Tarsus Pharmaceuticals, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Tarsus Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Bobak AzamianPresident, Chief Executive Officer and Director$2,510,396
Seshadri NeervannanChief Operating Officer$2,213,677
Leo Greenstein · this pageChief Financial Officer$835,443

The full Tarsus Pharmaceuticals compensation record

free company brief

This page is one person within Tarsus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tarsus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Leo Greenstein's compensation dossier · One-time report. No refunds.